Advances in Traditional Medicine

  • 제4권2호
  • /
  • Pages.82-86
  • /
  • 2004
  • /
  • 2662-4052(pISSN)
  • /
  • 2662-4060(eISSN)
경희대학교 융합한의과학연구소 (Kyung Hee Oriental Medicine Research Center)
권호 표지
DOI QR코드

DOI QR Code

Protective effect of Kohl-Chikni Dawa against galactose-induced cataract in rats

  • T.A., Siddiqui (Department of Surgery Faculty of Medicine (Unani), Hamdard University) ;
  • Z., Shadab (Department of Surgery Faculty of Medicine (Unani), Hamdard University) ;
  • N., Ayasha (Department of Kulliyat, Faculty of Medicine (Unani), Hamdard University) ;
  • S.H., Alavi (Department of Surgery Faculty of Medicine (Unani), Hamdard University)
  • 발행 : 2004.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The efficacy of Kohl-Chikni Dawa (KCD), a compound ophthalmic formulation of Unani medicine, to control cataract development was explored in rats fed 25% galactose with the diet for 6 months. When one drop of 3% KCD solution was applied (once and twice daily) in both eyes for 6 months in galactose-fed rats, a significant reduction of lens opacification was noticed. The morphological changes of the lenses were observed every month by slit-lamp biomicroscope. These results suggest that the local application of 3% KCD solution possesses anticataract effect in galactose-fed rats.

키워드

참고문헌

  1. Anonymous. (1981) National Formulary of Unani Medicine, Part I, pp. 58-62, Ministry of Health and Family Welfare, New Delhi, India.
  2. Anonymous. (1986) Physicochemical Standards of Unani Formulations, Part I, pp. 68-69, Central Council for Research in Unani Medicine, Ministry of Health and Family Welfare, New Delhi, India.
  3. Balaji M, Sasikala K, Ravindran T. (1992) Copper levels in human mixed, nuclear brunescence, and posterior subcapsular cataract. Br. J. Ophthalmol. 76, 668-669. https://doi.org/10.1136/bjo.76.11.668
  4. Beyer-Means A, Cruz E, Nicolas-Alexandre J, Varagiannis E. (1982) Xanthane-2-carboxylic acid effect on lens growth, hydration and proteins during diabetic cataract development. Arch. Int. Pharmacodyn. 259, 166-176.
  5. Biswas NR, Gupta SK, Das GK, Kumar N, Mongre PK, Haldar D, Beri S. (2001) Evaluation of ophthacare eye drops- a herbal formulation in the management of various ophthalmic disorders. Phytother. Res. 15, 618-620. https://doi.org/10.1002/ptr.896
  6. Chylack LT, Hemiques HF, Cheny HM, Tung WN. (1979) Efficacy of alrastatin an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. Ophthalmol. 86, 1579-1585. https://doi.org/10.1016/S0161-6420(79)35364-7
  7. Cook CS, Mc Gahan MC (1986) Copper concentration in cornea, iris, normal and cataractous lenses and intraocular fluids of vertebrates. Curr. Eye Res. 5, 69-77. https://doi.org/10.3109/02713688608995168
  8. Kabeeruddin M. (1938) Bayaz-e-Kabeer, Vol. II, pp. 134-135, Jayyad Press, Delhi, India.
  9. Khan MS. (1873) Ilaj-e-Nafeya, pp. 360, Matba Munshi Nawal Kishore, Lucknow, India.
  10. Khan MS. (1903) Ilaj-ul-Amraz, pp. 75, Matba Mujtabaie, Delhi, India.
  11. Khan Z. (1870) Qarabadeen-e-Zakai, pp. 321-322, Matba Munshi Nawal Kishore, Lucknow, India.
  12. Kinoshita JH. (1965) Cataracts in galactosemia. Invest. Ophthalmol. 4, 786-799.
  13. Mitchell HS. (1935) Cataract in rats fed on galactose. Proc. Soc. Exp. Biol. Med. 32, 971-973. https://doi.org/10.3181/00379727-32-7927
  14. Ono H, Nozawa Y, Hayano S. (1982) Effects of M-79, 175, an aldose reductase inhibitor, on experimental sugar cataracts. Nipp. Gank. Gakk. Zassh. 86, 1343-1350.
  15. Peterson MJ, Sarges R, Aldinger C, Mac Donald DP. (1979) CP-45, 634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 28, 456-461. https://doi.org/10.1016/0026-0495(79)90056-8
  16. Pirie A, Van Heyningen R. (1964) The effect of diabetes on the content of sorbitol, glucose, fructose acid inositol in the human lens. Exp. Eye Res. 3, 124-131. https://doi.org/10.1016/S0014-4835(64)80027-0
  17. Prashar S, Nath R. (1991) Studies on trace metals and metal-binding protein in human senile cataractous lens. In:. Ocular Pharmacology Recent Advances, edited by Gupta SK, pp. 49-56, Papyrus Publishing House, New Delhi, India.
  18. Racz P, Erdohelyi A. (1988) Cadmium, lead and copper concentration in normal and senile cataractous human lenses. Ophthalmol. Res. 20, 10-13. https://doi.org/10.1159/000266248
  19. Siddiqui T A, Shadab Z, Nishat I, Ayasha N, Zehra Z, Alavi SH. (2003) Anticataract activity of Kohl-Chikni Dawa- a compound ophthalmic formulation of Unani medicine in alloxan-diabetic rats. J. Ethnopharmacol. 86, 109-112. https://doi.org/10.1016/S0378-8741(03)00046-1
  20. Siddiqui TA, Zafar S, Nishat I, Ayasha N, Zehra Z, Alavi SH. (2002) Effect of Kohl-Chikni Dawa- a compound ophthalmic formulation of Unani medicine on naphthalene-induced cataracts in rats. BMC Comp. Alt. Med. 2, 13. https://doi.org/10.1186/1472-6882-2-13
  21. Siddiqui TA, Zafar S, Nishat I, Ayasha N, Zehra Z. (2001) Ocular safety assessment of Kohl-Chikni Dawa- a compound ophthalmic formulation of Unani medicine with special reference to Draize test in rabbits. Acta Manilana 49, 65-70.
  22. Simard-Duquesne N and Dvornik D. (1973) Galactititol accumulation and irreversible lens opacities in galactosemic rats. Invest. Ophthalmol. 12, 82-83.
  23. Sinard-Duquesne N, Greselin E, Gonzalez R, Dvornik D. (1985) Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, Tolrestat (42048). Proc. Soc. Exp. BioI. Med. 178, 599-605. https://doi.org/10.3181/00379727-178-42048
  24. Sipple TO. (1966) Changes in the water, protein, and glutathion contents of the lens in the course of galactose cataract development in rats. Invest. Ophthalmol. 5, 568-575.
  25. Swanson A, Trusdale AW. (1971) Elemental analysis in normal and cataractous human lens tissue. Biochem. Biophys. Res. Commun. 45, 1488-1496. https://doi.org/10.1016/0006-291X(71)90188-4